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Sirs:
High levels of serum low density lipoprotein cholesterol
(LDL-C) and low levels of high density lipoprotein cho-
lesterol (HDL-C) are well-known risk factors for premature
atherosclerotic vascular disease [1, 2]. They are targets for
primary and secondary prevention. Interpreting lipid pro-
ﬁles is part of the daily routine for a cardiologist. The most
common cause of low HDL-C in western society is meta-
bolic syndrome. More rare are primary lipid disorders (e.g.,
Tangier syndrome due to an ABCA transporter deﬁciency
or deﬁciency of apolipoprotein A1) and secondary causes
like (ab)use of androgens (Table 1). Extremely low serum
HDL levels are associated with an increased risk of death,
sepsis and malignancy [3]. A rare but important cause is
interference in the biochemical assay by paraproteins,
yielding an artifactually low HDL-C measurement result.
We present the case of a patient who had his lipid proﬁle
repeatedly tested over the course of 4 years and had pro-
gressive decline in HDL-C measurements.
A 74-year-old man presented with fever, cold chills,
vomiting, diarrhea and shortness of breath. He did not use
any chronic medication. Upon physical examination, he
was dyspnoeic with a respiratory rate of 30 per min, an
oxygen saturation of 87% at ambient air, a temperature of
39C, and a blood pressure of 170/120 mmHg with a heart
rate of 135 bpm. On auscultation of the heart, there was a
regular tachycardia without murmurs. Crackles and rhonchi
were present at the base of the right lung. There was no
lymphadenopathy or hepatosplenomegaly. The chest X-ray
revealed a large inﬁltration in the right lung. Respiratory
insufﬁciency and evolving sepsis required admittance to
the ICU with mechanical ventilation and vasopressive
medication. Initial antibiotic treatment consisted of moxi-
ﬂoxacin with a switch to penicillin G after blood cultures
grew Streptococcus pneumonia. The patient developed
renal insufﬁciency due to an acute tubulus necrosis,
requiring temporary continuous veno-venous haemoﬁltra-
tion. After 1 week, he could be transferred to the internal
medicine ward. Recovery and mobilization were relatively
slow in part due to a parapneumonic effusion. When the
patient was discharged to a revalidation center (37 days
after admission), vital parameters and renal function were
normalized.
Three months after his ﬁrst hospitalization he was
re-admitted with pneumonia. Re-evaluation of the labora-
tory reports of the ﬁrst hospital episode revealed at pre-
sentation an ESR of 132 mm/h and normochromic anemia
with a hemoglobin value of 6.0 mmol/l. Three months
before admission, a low HDL-C of 0.1 mmol/l had been
measured. Because of the recurrent nature of the infection,
an immune compromising condition was suspected. Mul-
tiple myeloma with paraproteinemia was detected with a
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microglobuline of 7.2 mg/l; plasma calcium was normal.
The skeletal survey showed no signs of lytic activity. A
peripheral blood smear showed rouleaux formation (pseudo
agglutination) of erythrocytes.
The bone marrow biopsy was hypercellullar, mainly
consisting of plasma cells. There was a monoclonal plasma
cell proliferation (47.2%), consistent with multiple mye-
loma. Immunophenotyping and in situ hybridization
showed a monoclonality for IgG-k. Flow cytometry
showed CD56, CD38, CD138 positivity and CD19 and
CD45 negativity (Fig. 2). According to the criteria of the
International Staging System for multiple myeloma, there
was a stage 3 multiple myeloma [8]. Therapy was started
with melfalan, prednisolon, thalidomide and later
bortezomib with dexamethason with good hematologic
response: IgG-k dropped to 3 g/l. After correction of the
paraproteinemia with this therapy HDL-C restored to a
level of 1.0 mmol/l (Table 2). Because of the prothromb-
ogenic side effects of thalidomide, acetylsalicylic acid was
added for prophylaxis. Besides a short hospital admission
due to leucopenic fever after 8 months, the patient was
symptom-free at 1-year clinical follow-up.
HDL-C measurements were initially performed on a
Hitachi 917 analyzer (Roche Diagnostics, Switzerland)
with HDL-C reagent (HDL-C plus second generation,
Roche Diagnostics, Switzerland). A reanalysis of the serum
sample with high paraproteins with a conventional
precipitation method (sodium phosphotungstate-MgCl2)
yielded a normal value for HDL-C of 1.2 mmol/l.
The case presented contains several learning points.
First, the laboratory charts disclose a steady decline of
HDL-C values over a period of 4 years, reﬂecting the
development of increasing amounts of paraproteins which
interfered in the HDL-C assay.
Secondly, interference of paraproteins with HDL-C
measurement can occur in various automated analyzers
[10–14]. Paraproteins may have unusual speciﬁcity for
various antigens, including actin, double-stranded DNA,
thyroglobulin, insulin, and apolipoprotein [15]. Further-
more, paraproteins may also interfere with the measure-
ment of HDL-C in homogeneous automated assays
[10–14]. Interference is most probably due to the formation
of a precipitate with the ﬁrst reagent [12]. The ﬁrst reagents
used in this assay consists of dextransulphate, MgSO4 and
a-cyclodextrin. These reagents are used to block the low
density lipoproteins (i.e. to make them inaccessible for the
later added cholesteroloxidase). In this way, only choles-
terol of HDL particles can be converted in cholestenone
and H2O2. Using peroxidase, the formed peroxide can
ﬁnally be converted into color, which can then be
Table 1 Differential diagnosis: Causes of low HDL-C values
[adapted from 4–7]
Primary disorders (rare)
Familial primary hypoalphalipoproteinemia
Nonfamilial hypoalphalipoproteinemia
Familial hypoalphalipoproteinemia with hypertriglyceridemia
Familial HDL-cholesterol deﬁciency and Tangier disease
Elevated CETP activity
Lipoprotein lipase deﬁciency
LCAT deﬁciency
Secondary disorders
Insulin resistance (elevated triglyceride levels, overweight and
obesity, physical inactivity, type 2 diabetes)
Acute infections and other inﬂammatory conditions
Drugs (beta blockers, benzodiazepines, anabolic steroids,
progestins, diuretics)
Cigarette smoking
Low-fat diet
Artifactually low in gammopathies
Fig. 1 Densitometric scan of
protein electrophoresis (left)
with ﬁve protein fractions from
left to right: albumin, alpha 1,
alpha 2, beta and gamma.
Electrophoresis (ELP) and
immunoﬁxation of serum (right)
with anti-IgG (G), anti IgA (A),
anti IgM (M), anti-kappa (K)
and anti lambda (L)
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123colorimetrically detected and used as a measure for the
amount of HDL-C [16]. Interference of paraproteins by
precipitate formation in the ﬁrst step gives falsely increased
absorbance of the blank and falsely decreased HDL-C
values after subtraction from the ﬁnal absorbance. This
interference is unpredictable and independent of the
Fig. 2 Immunophenotyping of bone marrow aspirate by ﬂow
cytometry. FACS (ﬂuorescence activated cell sorting) plots of CD
56–CD 19, CD 138–CD 38, CD 117–CD 45 were consistent with the
diagnosis multiple myeloma IgG-k. Myeloma cells are typically
CD56, CD38, CD138-positive and CD19 and CD45-negative [9]
Table 2 Chart with results of laboratory tests
Reference values Years before and after presentation
-4 -3 -10 1
Cholesterol 3.5–5.0 mmol/l 4.9 4.1 3.8 3.6 5.5
HDL-C 0.9–1.7 mmol/l 0.9 0.8 0.5 0.1 1.0
LDL-C \4.4 mmol/l 2.8 2.5 2.0 0 2.9
Triglycerides 0.6–2.2 mmol/l 2.6 1.8 2.8 1.8 3.5
IgA 0.70–4.00 g/l 0.22 0.30
IgG 7.0–16.0 g/l 60.3 6.9
IgM 0.40–2.30 g/l 0.07 0.24
M-protein Absent (g/l) 41.7 3.7
Total protein 60–80 g/l 111 57
Both total and HDL-cholesterol concentrations decrease over the years until very low HDL-C levels were measured. After correction of the
paraproteinemia with successive therapy of melfalan-prednisolon and later bortezomib-dexamethason, cholesterol levels restored to initial values
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123quantity or isotype of paraprotein [10–14]. In the conven-
tional precipitation method for measuring HDL-C, MgCl2
and sodium phosphotungstate are manually added reagents
to serum. They cause low density lipoproteins like chylo-
microns, VLDL and LDL to precipitate and separate from
high density lipoproteins, which remain in the supernatant.
Total cholesterol is measured in the supernatant as a
measure for the amount of HDL-C. This manual one-step
precipitation assay is not interfered by paraproteins. The
difference in HDL-C between the homogenous assay
(0.1 mmol/l) and the manual precipitation assay
(1.2 mmol/l) is therefore most probably due to the presence
of paraproteins. This suggestion is supported by the
improvement of HDL-C (1.0 mmol/l) after correction of
the paraproteinemia in response to therapy.
Thirdly, according to some reports, measuring (almost)
undetectable HDL-C values is extremely rare. In 2002, only
16 (0.06%) out of 247.111 HDL-C measurements in the
Clinical Laboratory of the San Francisco Medical Center
(University of California) yielded undetectable values [11];
paraprotein interference associated with undetectable
HDL-C values was identiﬁed in 3 (16%) of 19 paraprotein-
containing specimens. In another small series of patients
with known monoclonal paraproteins, an extremely low or
undetectable HDL-C value was found in 4 out of 13 patients
[12]. Recently, Roche Diagnostics has replaced the second
generation HDL-C test by a new third generation test with
an improved start reagent (R1). Although the frequency of
the interference is further reduced we have observed few
other cases with falsely low HDL-C caused by paraprotein
interference since this replacement.
Fourthly, because of the anemia (and extremely high
ESR) on the ﬁrst day of acute illness, an underlying chronic
condition could have been considered earlier. Would a
more earlier recognition of the underlying multiple mye-
loma have beneﬁtted the patient? The extremely low
HDL-C values were measured 3 months before the ﬁrst
hospital admittance by the general practitioner. The initial
treatment of the patient would not have been different, but
a recurrence of the pneumonia might have been postponed
by an earlier treatment of the multiple myeloma.
Thus, when measuring extremely low HDL-C levels on
routine cardiovascular screening, cardiologists and other
physicians may consider the presence of multiple myeloma
as a relatively rare but clinically important differential
diagnosis.
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